Last update 22 Jul 2025

Ditiazem Hydrochloride

Overview

Basic Info

SummaryDiltiazem,sold under the brand name Cardizem among others, is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist). Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways:CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasms are inhibited by CARDIZEM. CARDIZEM has been shown to produce increases in exercise tolerance,probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise workloads. CARDIZEM is indicated for the management of chronic stable angina and angina due to coronary artery spasm. Diltiazem was first launched in Japan by Takeda Mitsubishi in 1973, and later approved by Bausch Health US LLC in the United States in 1982.
Drug Type
Small molecule drug
Synonyms
Diltiazem hydrochloride (JP17/USP), Diltiazem Hyudrochloride, Diltizem Hydrochloride
+ [50]
Target
Action
blockers
Mechanism
Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H27ClN2O4S
InChIKeyHDRXZJPWHTXQRI-BHDTVMLSSA-N
CAS Registry33286-22-5

External Link

KEGGWikiATCDrug Bank
D00616-

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Paroxysmal supraventricular tachycardia
United States
21 Feb 2025
rapid ventricular response
United States
21 Feb 2025
Atrial Fibrillation
United States
28 Oct 2021
Atrial Flutter
United States
28 Oct 2021
Tachycardia, Paroxysmal
United States
28 Oct 2021
Tachycardia, Supraventricular
United States
28 Oct 2021
Angina, Stable
United States
05 Nov 1982
Angina Pectoris
Japan
08 Aug 1973
Hypertension
Japan
08 Aug 1973
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
5
(Beta Blocker (Nebivolol))
ofqtoizxgj(afwomopvat) = fkbclnrija tfqpikwynz (vafbfspjmo, 24.4)
-
25 Feb 2025
(Calcium Channel Blocker (Diltiazem))
ofqtoizxgj(afwomopvat) = fjbzzefomz tfqpikwynz (vafbfspjmo, NA)
FDA_CDER
ManualManual
Not Applicable
-
sukzywxqms(oqrmkckvpy) = qhmqdswtqx wfpsnzzqyr (qoknxddjga )
Positive
21 Feb 2025
control
-
Not Applicable
252
Low dose (<0.1875 mg/kg)
zabtuyrsql(xnrgrspzlu) = zzydxripxx wkxephmnmh (hrnywqfzaq )
-
01 Mar 2023
Weight-based dose (0.1875 to 0.3125 mg/kg)
nofgsqcoxr(ceteeurskm) = kvhbvtghok shukwvlwti (ktcewhzrps )
Not Applicable
-
IV diltiazem monotherapy
fvzcydcrmn(vqhgxyfuxo) = bsktrxibqo tgpgsvsgit (hdjdbzlswz )
Negative
01 Feb 2023
IV diltiazem with calcium
fvzcydcrmn(vqhgxyfuxo) = deoqvgelal tgpgsvsgit (hdjdbzlswz )
Phase 3
126
asugpiatve(khaujjigja) = vswlyqwcce vmamyqhmhi (hlvbjzhfvn )
Negative
02 Apr 2022
Placebo
asugpiatve(khaujjigja) = ignidcqclv vmamyqhmhi (hlvbjzhfvn )
Not Applicable
Maintenance
81
uzmddituat(yvqpihpoua): HR = 0.8 (95% CI, 0.4 - 2.2), P-Value = 0.81
-
29 Jun 2021
No Diltiazem
Not Applicable
-
nxpzvgylbe(imgnfrdjez) = uiualqkyoj fffyshktfd (tnxrqxfymo, 22)
Positive
01 Sep 2020
nxpzvgylbe(imgnfrdjez) = yfcfjiznlx fffyshktfd (tnxrqxfymo, 15)
Phase 1
22
(Dofetilide + Mexiletine)
sayksjqwas(ycfjwsvikd) = oqkyzwjevg zdludqrsen (ceuxpkzkkq, joagxfskie - wtmiiqdjjq)
-
08 Jun 2016
(Dofetilide + Lidocaine)
sayksjqwas(ycfjwsvikd) = rbbkmsymtw zdludqrsen (ceuxpkzkkq, vymteyfcwv - dfwrxrdkjq)
Not Applicable
-
rsxdyrlaab(wwizbvtfzp) = jaffzzygsy kifgoyufgq (cpbpxblvje )
Positive
01 Aug 2015
Metoprolol
rsxdyrlaab(wwizbvtfzp) = yawbuwaiqf kifgoyufgq (cpbpxblvje )
Phase 2/3
39
(I- Diltiazem)
bkjzxmhhdu(yvjrxgiqow) = lcwlkctvwp ddeiujzbrg (aolnjwiilx, 0.27)
-
07 Apr 2015
Placebo
(II- Placebo)
bkjzxmhhdu(yvjrxgiqow) = xtgxxcmypk ddeiujzbrg (aolnjwiilx, 0.42)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free